Precision Medicine in Systemic Mastocytosis
暂无分享,去创建一个
G. Gaidano | A. Mahmoud | A. Patriarca | R. Boldorini | A. Gennari | M. Nicolosi | E. Crisà | A. Andorno | A. M. Mahmoud
[1] J. Winkler,et al. Health-related quality of life and influencing factors in adults with non-advanced mastocytosis - a cross-sectional study and qualitative approach. , 2021, The journal of allergy and clinical immunology. In practice.
[2] A. Dorrance. "Mast"ering drug discovery with iPSCs. , 2021, Blood.
[3] R. Norman,et al. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. , 2021, Journal of clinical epidemiology.
[4] M. Szczyrek,et al. Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis , 2021, Journal of clinical medicine.
[5] C. Kelly,et al. The management of metastatic GIST: current standard and investigational therapeutics , 2021, Journal of Hematology & Oncology.
[6] A. Orazi,et al. Acute aleukemic mast cell leukemia: Report of a case and review of the literature , 2020, Leukemia research reports.
[7] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[8] M. Mancini,et al. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy , 2020, International journal of molecular sciences.
[9] S. Mustjoki,et al. Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis , 2020, bioRxiv.
[10] T. George,et al. New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis. , 2020, Blood.
[11] C. Paul,et al. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[12] D. Cella,et al. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index , 2020, Leukemia.
[13] L. French,et al. Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study) , 2020, Dermatology.
[14] J. D. van der Walt,et al. The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review , 2019, Pathobiology.
[15] M. Vignetti,et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy , 2019, Leukemia.
[16] M. Triggiani,et al. Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches , 2019, International journal of molecular sciences.
[17] Stacie L. Bulfer,et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. , 2019, Cancer cell.
[18] J. Butterfield,et al. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. , 2019, The journal of allergy and clinical immunology. In practice.
[19] L. Cro,et al. A case report of systemic mastocytosis associated with multiple hematologic non–mast cell lineage diseases , 2019, Hematological oncology.
[20] N. Cross,et al. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. , 2019, Leukemia research.
[21] A. Pardanani. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management , 2018, American journal of hematology.
[22] E. Ranheim,et al. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[23] C. Bebbington,et al. AK002, a Novel Humanized Monoclonal Antibody to Siglec-8, Inhibits Mast Cell Activity and Depletes Eosinophils in Ex Vivo Bone Marrow Tissue from Patients with Systemic Mastocytosis , 2018, Blood.
[24] A. Tefferi,et al. Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis , 2018, American journal of hematology.
[25] P. Guglielmelli,et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. , 2018, Blood advances.
[26] K. Roskin,et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. , 2018, Blood advances.
[27] A. Tefferi,et al. Practice‐relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm , 2018, American journal of hematology.
[28] A. Tefferi,et al. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory‐specific incidence and prognostic impact among 348 informative cases , 2018, American journal of hematology.
[29] S. Rosati,et al. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. , 2018, The Journal of allergy and clinical immunology.
[30] S. Verstovsek,et al. Patient Perceptions in Mast Cell Disorders. , 2018, Immunology and allergy clinics of North America.
[31] Yvette N. Lamb,et al. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis , 2018, Drugs.
[32] W. Hofmann,et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis , 2018, Genes, chromosomes & cancer.
[33] J. Merker,et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial , 2018, Leukemia.
[34] U. Borate,et al. How we diagnose and treat systemic mastocytosis in adults , 2018, British journal of haematology.
[35] A. Gardino,et al. A precision therapy against cancers driven by KIT/PDGFRA mutations , 2017, Science Translational Medicine.
[36] H. Kluin-Nelemans,et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] F. Lo‐Coco,et al. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? , 2017, Blood.
[38] I. Alvarez-Twose,et al. Insights in Anaphylaxis and Clonal Mast Cell Disorders , 2017, Front. Immunol..
[39] M. Mancini,et al. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis , 2017, Leukemia.
[40] A. Tefferi,et al. Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survival , 2016, American journal of hematology.
[41] H. Deeg,et al. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[42] A. Órfão,et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature , 2016, Oncotarget.
[43] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[44] W. Hofmann,et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis , 2016, European journal of clinical investigation.
[45] C. Brooks,et al. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value , 2016, Leukemia.
[46] G. Superti-Furga,et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth , 2016, Leukemia.
[47] B. Grosbois,et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. , 2015, Blood.
[48] Martin C. Müller,et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study , 2015, Journal of Cancer Research and Clinical Oncology.
[49] T. Haferlach,et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event , 2015, Leukemia.
[50] R. Gaillard,et al. Neuropsychological features of adult mastocytosis. , 2014, Immunology and allergy clinics of North America.
[51] C. Bindslev‐Jensen,et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis , 2014, American journal of hematology.
[52] G. Cruse,et al. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. , 2014, Immunology and allergy clinics of North America.
[53] Florent Langenfeld,et al. Molecular defects in mastocytosis: KIT and beyond KIT. , 2014, Immunology and allergy clinics of North America.
[54] K. Brockow. Epidemiology, prognosis, and risk factors in mastocytosis. , 2014, Immunology and allergy clinics of North America.
[55] G. Stefanzl,et al. The pan‐Bcl‐2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells , 2014, Journal of leukocyte biology.
[56] A. Kohlmann,et al. Comprehensive mutational profiling in advanced systemic mastocytosis. , 2013, Blood.
[57] H. Sokol,et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. , 2013, The Journal of allergy and clinical immunology.
[58] Wei Yang,et al. The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.
[59] A. Órfão,et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. , 2013, Blood.
[60] S. Verstovsek,et al. Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components , 2013, American journal of hematology.
[61] K. Sotlar,et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis , 2011, Modern Pathology.
[62] J. Launay,et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients , 2010, Annals of the rheumatic diseases.
[63] A. Tefferi,et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.
[64] A. Tefferi,et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine , 2009, American journal of hematology.
[65] A. Tefferi,et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.
[66] A. Tefferi,et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.
[67] M. Dieguez,et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA) , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[68] A. Órfão,et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations * , 2007, British journal of haematology.
[69] W. Pickl,et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. , 2007, Blood.
[70] D. Fabbro,et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.
[71] C. Chen,et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.
[72] A. Tefferi,et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. , 2004, Leukemia research.
[73] K. Sotlar,et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge , 2004, Journal of Clinical Pathology.
[74] A. Órfão,et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.
[75] B. Bain,et al. Cytogenetic and Molecular Genetic Abnormalities in Systemic Mastocytosis , 2002, Acta Haematologica.
[76] M. Tomonaga,et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. , 1998, Internal medicine.
[77] W. Stremmel,et al. Clinical stable systemic mastocytosis with interferon alpha 2b therapy. , 1997, Journal of internal medicine.
[78] D. Metcalfe,et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. , 1996, Leukemia & lymphoma.
[79] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[80] A. Torrelo,et al. Urticaria Pigmentosa: A Review of 67 Pediatric Cases , 1994, Pediatric dermatology.
[81] R. Spritz,et al. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. , 1992, Oncogene.
[82] C. Decastro,et al. Cloning and structural analysis of the human c-kit gene. , 1992, Oncogene.
[83] D. Metcalfe,et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. , 1991, Journal of immunology.
[84] R. Caplan. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. , 1963, Archives of dermatology.
[85] T. Haferlach,et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.
[86] P. Valent. Mast cell leukemia--a rare form of myeloid leukemia. , 2002, Wiener klinische Wochenschrift.